With WP1, we’re studying the long-term health outcomes of people living with multiorgan autoimmune and inflammatory diseases. By building on a cohort of patients with multiorgan inflammatory disorders anchored around skin diseases such as psoriasis and Hidrosadenitis Suppurativa established in 2019 to 2022, we want to better understand:

• which patients respond best to which advanced treatments.
• who may be at higher risk of developing complications and severe co-morbidities.

This research will help shape more personalised treatment strategies and guide future clinical care.

WP1 is creating a robust foundation for the DREAM Center.

By providing insights into and prognostic markers for long-term health outcomes, we will help:

• doctors make more informed treatment decisions
• researchers design smarter clinical trials
• policymakers improve healthcare systems

Most importantly, this work ensures that patients with complex autoimmune and inflammatory diseases get the right care, at the right time, for better long-term health.

We will perform a clinical follow-up study on the patients from the 2019-2022 cohort. We will invite the patients to a clinical follow-up visit, where we will not only examine their present health but also ask for biosamples to be analysed in WP2.

Examination and biosampling will include:

• blood tests and other laboratory analyses.
• patient-reported outcomes (quality of life, daily functioning, symptoms).
• clinician assessments of disease activity.
• data on healthcare use and work productivity.

Together, this forms the basis of a dedicated patient cohort for multiorgan autoinflammatory diseases (MAID). This cohort will not only strengthen current research but also serve as a foundation for future clinical trials.

Between 2019 and 2022, 213 patients took part in a clinical trial. They received either a multidisciplinary treatment protocol (MDT) or standard care. Clinical data, biological samples, and patient-reported outcomes were collected and stored in a secure database and biobank.

Now, by collecting new data from the same patients 3–6 years later, we can track:

• how their health has changed over time.
• which treatments show the best long-term benefits.
• which biomarkers predict patient outcomes.

• Understand long-term treatment effects and identify key biomarkers.
• Standardise workflows for follow-up and data collection across DREAM center.
• Ensure data quality, governance, and compliance with ethical standards.

• A complete clinical dataset combining past and new follow-up data.
• Predictive factors and biomarkers to guide personalised treatment.
• Evidence on the long-term impact of MDT interventions on disease control, healthcare use, and metabolic risks.
• Practical frameworks and protocols for patient follow-up in future clinical research.